About the Dana-Farber Cancer Institute, a teaching affiliate of Harvard Medical School
Dana-Farber Cancer Institute The Dana-Farber Cancer Institute, founded in 1947, is a specialist cancer hospital affiliated with Harvard Medical School, a federally designated comprehensive cancer treatment centre, and has produced one Nobel Laureate in medicine.
Dana-Farber Cancer Institute's specialties
Clinical aspects of cancer gene targeting therapy, cancer immunotherapy, cancer endocrine therapy, cancer biotherapy, cancer vaccines, etc.
The Dana-Farber Cancer Institute is a national leader in the treatment of adult tumours, and has been ranked first in the nation in the treatment of paediatric tumours for many years.
Since its inception, the Dana-Farber Cancer Institute has been dedicated to providing professional and efficient medical care to cancer patients, while improving the understanding, diagnosis, treatment and prevention of cancer and related diseases through cutting-edge research. As an affiliate of Harvard Medical School and a federally designated comprehensive cancer centre, the Dana-Farber Cancer Institute also trains a new generation of physicians and specialists to improve public health care in high-risk and underserved areas, and to disseminate advanced treatments and scientific discoveries throughout the United States and the world.
Currently, the Dana-Farber Cancer Institute has a staff of 4,000 and sees approximately 300,000 patients each year. With more than 700 clinical trials available each year, the Institute has gained a worldwide reputation for its dual clinical and research strengths.
In 1996, the Dana-Farber/Bregen Cancer Centre was established as a joint venture between the Breggen and Women's Hospital and the Dana-Farber Cancer Institute, a cancer treatment and research institute. In general, cancer patients are seen in outpatient clinics at the Dana-Farber Cancer Institute, while inpatient treatment takes place at the Brigham and Women's Hospital. The two institutions are connected by a sky bridge and are combined to form the Dana-Farber/Bregan Cancer Centre. It is consistently ranked as one of the leading and most renowned cancer treatment centres in the country.
The Dana-Farber/Bregen Cancer Centre is a combination of a cancer research institute and a hospital, creating 12 cancer specialties that combine integrative medicine, surgery, radiotherapy and new clinical trials to treat cancers including lung, breast, stomach, oesophagus, colorectal, liver, pancreas, leukaemia, multiple myeloma, neurological tumours, prostate, kidney, cervical, osteosarcoma, head and neck, skin, melanoma and more. skin cancer, melanoma and many more. His milestones include the development of the #1 and most important biomarker for ovarian cancer, the CA-125 test; pioneering new methods for the evaluation and treatment of prostate cancer; developing advanced surgical techniques for brain surgery; and pioneering selective internal radiation therapy for the liver.
The current Director is Professor Edward J. Benz Jr. who is a professor at Harvard Medical School, an NIH grant approver and a world-renowned expert in the treatment of paediatric oncology.
Professor Joseph H. Antin, Director of the Stem Cell Transplantation Program, is the Chairman of the American Center for Blood and Marrow Transplantation and is well known in the field of stem cell transplantation and bone marrow transplantation, aplastic anemia and paroxysmal nocturnal haemoglobinuria, etc. Professor Judy Garber is the President of the American Association for Cancer Research and is involved in research on cancer genetics and prevention.
Digestive Oncology Centre
The Centre uses new technologies to provide patients with effective treatment modalities, including many innovative treatments and cutting-edge therapeutic techniques for oesophageal, gastric, colorectal, gallbladder, liver and bile duct cancers, pancreatic cancer and rare gastrointestinal interstitial tumours.
Charles S. Fuchs, Director, Gastrointestinal Cancer Center, Dana-Farber Cancer Hospital, Harvard Medical School, USA; Professor, Harvard Medical School, USA; Member, NCCN Cancer Practice Guidelines Expert Panel; One of America's Top Doctors 2011; Lee Nadler Extra Mile Award 2007; Tisch Clinical Contribution Award 2007. He received the National Institutes of Health (NIH) College Award in 1995. His research focuses on biochemical markers of gastrointestinal cancer risk, molecular prediction of prognosis in patients with colorectal and pancreatic cancer, and research to identify new targets for cancer therapy.
Lymphoma Centre
The Dana-Farber Cancer Institute is a world-renowned centre for the treatment of lymphoma. The Centre has extensive experience in the diagnosis and treatment of Hodgkin's lymphoma and over 60 non-Hodgkin's lymphomas, including both common and rare types of disease. The Centre treats all stages and types of lymphoma, including: B-cell lymphoma, T-cell lymphoma, large granular lymphocytic leukaemia and more.
Margaret A. Shipp is Chief of the Division of Haematology Oncology, Director of the Lymphoma and Myeloma Centre and Professor at Harvard Medical School, USA. Arnold S. Freedman is the Clinical Director of the Lymphoma Centre and is working on new treatments for non-Hodgkin's lymphoma.
